Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -142,163 | 25,291 | 480,370 | 492,608 | 398,837 |
| Depreciation Amortization | 568,312 | 576,741 | 314,124 | 303,870 | 265,540 |
| Income taxes - deferred | -75,292 | -67,428 | -50,903 | -35,884 | -24,006 |
| Accounts receivable | 35,737 | 21,612 | -33,434 | -150,570 | -26,633 |
| Accounts payable and accrued liabilities | 2,869 | -14,271 | -20,427 | -2,652 | 44,901 |
| Other Working Capital | 14,081 | -30,329 | -102,380 | -152,554 | 42,942 |
| Other Operating Activity | 334,102 | 222,961 | 96,548 | 164,822 | 59,218 |
| Operating Cash Flow | $737,646 | $734,577 | $683,898 | $619,640 | $760,799 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -20,076 | -52,876 | -54,215 | -158,274 | -45,555 |
| PPE Investments | -219,152 | -232,967 | -318,528 | -324,733 | -228,772 |
| Net Acquisitions | 17,441 | -5,479 | -194,785 | -120,117 | -1,170,401 |
| Sale Of Investment | 9,102 | 41,687 | 6,667 | 4,549 | 6,532 |
| Other Investing Activity | 3,364 | 4,549 | -2,294 | -9,347 | 264 |
| Investing Cash Flow | $-209,321 | $-245,086 | $-563,155 | $-607,922 | $-1,437,932 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 1,227,534 | 1,081,581 | 776,353 | 2,952,430 | 6,951,113 |
| Debt Repayment | -1,349,317 | -1,493,769 | -851,676 | -2,932,636 | -6,281,132 |
| Common Stock Issued | 714 | 23,878 | 25,597 | 25,110 | 45,652 |
| Common Stock Repurchased | -360,673 | -119,175 | -24,155 | -38,651 | -40,707 |
| Other Financing Activity | -54,984 | -43,442 | -11,640 | -48,650 | -2,328 |
| Financing Cash Flow | $-536,726 | $-550,927 | $-85,521 | $-42,397 | $672,598 |
| Exchange Rate Effect | 18,828 | -17,474 | 8,044 | 25,579 | 17,730 |
| Beginning Cash Position | 205,570 | 284,480 | 241,214 | 246,314 | 233,119 |
| End Cash Position | 215,997 | 205,570 | 284,480 | 241,214 | 246,314 |
| Net Cash Flow | $10,427 | $-78,910 | $43,266 | $-5,100 | $13,195 |
| Free Cash Flow | |||||
| Operating Cash Flow | 737,646 | 734,577 | 683,898 | 619,640 | 760,799 |
| Capital Expenditure | -219,152 | -232,967 | -318,528 | -324,733 | -228,772 |
| Free Cash Flow | 518,494 | 501,610 | 365,370 | 294,907 | 532,027 |